Victory Capital Management
LOGC

Victory Capital Management’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Victory Capital Management’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-11,638
Closed -$58K – 3537
2020
Q1 		$58K Buy
11,638
+8,638
+288% +$67.2K ﹤0.01% 2711
2019
Q4 		$22K Sell
3,000
-3,200
-52% -$28.9K ﹤0.01% 2615
2019
Q3 		$67K Buy
6,200
+3,200
+107% +$34.2K ﹤0.01% 2572
2019
Q2 		$39K Hold
3,000
– – ﹤0.01% 1762
2019
Q1 		$30K Hold
3,000
– – ﹤0.01% 1731
2018
Q4 		$31K Buy
+3,000
New +$36.2K ﹤0.01% 1726

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Victory Capital Management's LOGC Position: Q2 2020 in Review

Victory Capital Management sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q2 2020, closing a stake of 11,638 shares — an estimated $58K sold.

Victory Capital Management first reported a position in LOGC in Q4 2018 and held it in 6 quarters. The position peaked at $67K in Q3 2019. 43 funds tracked by Wall St. Rank hold LOGC as of Q2 2020.

  • Victory Capital Management reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 11,638 LogicBio Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $58K.
  • Victory Capital Management first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 6 quarters.
  • Victory Capital Management's LogicBio Therapeutics, Inc. Common Stock position peaked at $67K in Q3 2019.
  • 43 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.